IT9048113A0 - FORMULATIONS WITH PROTRACT RELEASE OF WATER SOLUBLE PEPTIDES (CASE 600-7110) - Google Patents

FORMULATIONS WITH PROTRACT RELEASE OF WATER SOLUBLE PEPTIDES (CASE 600-7110)

Info

Publication number
IT9048113A0
IT9048113A0 IT4811390A IT4811390A IT9048113A0 IT 9048113 A0 IT9048113 A0 IT 9048113A0 IT 4811390 A IT4811390 A IT 4811390A IT 4811390 A IT4811390 A IT 4811390A IT 9048113 A0 IT9048113 A0 IT 9048113A0
Authority
IT
Italy
Prior art keywords
protract
formulations
release
case
water soluble
Prior art date
Application number
IT4811390A
Other languages
Italian (it)
Other versions
IT9048113A1 (en
IT1241460B (en
Inventor
David Bodmer
Jones W Fong
Thomas Kissel
Hawkins V Maulding
Oskar Nagele
Jane E Pearson
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IT9048113A0 publication Critical patent/IT9048113A0/en
Publication of IT9048113A1 publication Critical patent/IT9048113A1/en
Application granted granted Critical
Publication of IT1241460B publication Critical patent/IT1241460B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
IT48113A 1989-07-07 1990-07-05 PROTRACT SALE FORMULATIONS OF WATER SOLUBLE PEPTIDES (CASE 600-7110) IT1241460B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US41134789A 1989-09-22 1989-09-22

Publications (3)

Publication Number Publication Date
IT9048113A0 true IT9048113A0 (en) 1990-07-05
IT9048113A1 IT9048113A1 (en) 1992-01-05
IT1241460B IT1241460B (en) 1994-01-17

Family

ID=27007654

Family Applications (1)

Application Number Title Priority Date Filing Date
IT48113A IT1241460B (en) 1989-07-07 1990-07-05 PROTRACT SALE FORMULATIONS OF WATER SOLUBLE PEPTIDES (CASE 600-7110)

Country Status (27)

Country Link
JP (5) JPH0832624B2 (en)
KR (2) KR100303681B1 (en)
AT (1) AT406225B (en)
AU (2) AU641407B2 (en)
BE (1) BE1004486A3 (en)
CA (1) CA2020477C (en)
CH (1) CH685230A5 (en)
CY (1) CY1965A (en)
DE (2) DE4042752B4 (en)
DK (1) DK175849B1 (en)
FI (3) FI108611B (en)
FR (1) FR2649319A1 (en)
GB (2) GB2234896B (en)
GR (1) GR1001121B (en)
HK (2) HK97695A (en)
HU (2) HU221294B1 (en)
IE (2) IE64411B1 (en)
IL (3) IL131880A (en)
IT (1) IT1241460B (en)
LU (1) LU87764A1 (en)
MY (1) MY106722A (en)
NL (1) NL195027C (en)
NO (2) NO302928B1 (en)
NZ (1) NZ234384A (en)
PT (1) PT94628B (en)
SE (1) SE512992C2 (en)
SG (1) SG26416G (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (en) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft PROCEDURE FOR OBTAINING BIOLOGICAL DEGRADABLE MICROPARTICLES WITH LONG TERM ACTION
CH683149A5 (en) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
DE4218510A1 (en) * 1992-06-02 1993-12-09 Pharmatech Gmbh Process for the preparation of biodegradable polyesters
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
JP2944419B2 (en) * 1993-05-10 1999-09-06 ノバルティス アクチエンゲゼルシャフト Stability of pharmacologically active ingredients in sustained release compositions
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
ATE288270T1 (en) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv MICRO-ENCAPSULED 1,2-BENZAZOLE
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
AU717113B2 (en) 1995-11-09 2000-03-16 Health Protection Agency Microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (en) 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (en) 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (en) * 2000-06-28 2003-07-22 동국제약 주식회사 Preparation Method for Sustained Release Microparticles by Multiple Emulsion Method and Micropartic les Thereof
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
DK1343480T4 (en) 2000-12-21 2016-04-18 Alrise Biosystems Gmbh Induced phase transition method for the preparation of microparticles containing hydrophobic active agents.
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
AR044852A1 (en) * 2003-06-24 2005-10-05 Novartis Ag A PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION THAT INCLUDES A SOMATOSTATINE ANALOG
EP2462923A3 (en) * 2003-07-18 2012-08-29 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
CN1921880A (en) * 2004-02-26 2007-02-28 独立行政法人科学技术振兴机构 Protein drug sustained-release microparticle preparation for injection and process for producing the same
DE102004053373A1 (en) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Invention relating to nano / meso-fiber anisometric particles in the form of nano / meso-fiber tubes, cables and their curved or branched modifications
KR100741867B1 (en) * 2005-07-05 2007-07-24 전북대학교산학협력단 Preparation method of double-layered sphere using oil-in-water and solvent evaporation
CA2631811C (en) * 2005-12-22 2017-06-20 Novartis Ag Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
KR100816065B1 (en) * 2006-11-27 2008-03-24 동국제약 주식회사 Preparation method of sustained-release microcapsules having good initial burst inhibiting property and the microcapsules thereby
KR101921800B1 (en) 2008-01-30 2018-11-23 노파르티스 아게 Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
RU2013119811A (en) * 2010-09-30 2014-11-10 Эвоник Корпорейшн METHOD FOR REMOVING RESIDUAL ORGANIC SOLVENT FROM MICROPARTICLES
US20120083444A1 (en) * 2010-09-30 2012-04-05 Brenda Perkins Emulsion Method For Preparing Low Residual Solvent Microparticles
TW201605488A (en) 2013-10-15 2016-02-16 大塚製藥股份有限公司 Drug for preventing and/or treating polycystic kidney disease
KR102464650B1 (en) 2016-05-03 2022-11-10 엘에스일렉트릭(주) Current limiting device of circuit breaker
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH649217A5 (en) * 1977-08-25 1985-05-15 Sandoz Ag BROMOCRIPTIN CONTAINING MICROCAPSULES.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
ATE2512T1 (en) * 1979-11-27 1983-03-15 Sandoz Ag POLYPEPTIDES, PROCESSES FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE POLYPEPTIDES AND THEIR USE.
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
ATE37983T1 (en) * 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
CH656884A5 (en) * 1983-08-26 1986-07-31 Sandoz Ag POLYOLESTERS, THEIR PRODUCTION AND USE.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (en) * 1985-04-11 1994-08-03 住友製薬株式会社 Sustained release formulation
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (en) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd Preparation of sustained release preparation
CH660302A5 (en) * 1984-10-17 1987-04-15 Debiopharm Sa HETEROGENEOUS PHASE MICRO-ENCAPSULATION PROCESS OF WATER-SOLUBLE DRUG SUBSTANCES.
DE3678308D1 (en) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd METHOD FOR PRODUCING MICROCAPSULES.
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (en) * 1986-03-06 1996-10-02 日本原子力研究所 Process for producing sustained-release drug complex composed of polylactone
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (en) * 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (en) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (en) * 1987-11-11 1989-05-24 Hoechst Ag METHOD FOR PRODUCING BIODEGRADABLE MICRO-CAPSULES OF WATER-SOLUBLE PEPTIDES AND PROTEINS AND MICRO-CAPSULES OBTAINED BY THIS PROCESS
JP2653255B2 (en) * 1990-02-13 1997-09-17 武田薬品工業株式会社 Long-term sustained release microcapsules

Also Published As

Publication number Publication date
DK162590D0 (en) 1990-07-05
JPH0368511A (en) 1991-03-25
DE4021517B4 (en) 2009-04-09
HK197496A (en) 1996-11-08
NO320444B1 (en) 2005-12-05
NL195027B (en) 2003-08-01
SG26416G (en) 1995-09-01
IE64216B1 (en) 1995-07-26
HU903974D0 (en) 1990-11-28
NO302928B1 (en) 1998-05-11
IL131881A (en) 2001-12-23
IT9048113A1 (en) 1992-01-05
KR100442931B1 (en) 2004-08-02
IL131880A (en) 2001-12-23
NL195027C (en) 2003-12-02
HU221294B1 (en) 2002-09-28
DE4042752B4 (en) 2009-05-07
PT94628A (en) 1991-03-20
AU641407B2 (en) 1993-09-23
SE9002364L (en) 1991-01-08
FR2649319A1 (en) 1991-01-11
GB2234896A (en) 1991-02-20
GR1001121B (en) 1993-04-28
CA2020477C (en) 2000-11-21
KR100303681B1 (en) 2002-05-16
CH685230A5 (en) 1995-05-15
NZ234384A (en) 1994-05-26
SE9002364D0 (en) 1990-07-05
CA2020477A1 (en) 1991-01-08
FI903429A0 (en) 1990-07-06
MY106722A (en) 1995-07-31
FI109543B (en) 2002-08-30
AU5874690A (en) 1991-01-10
HU211602A9 (en) 1995-12-28
GB2265311A (en) 1993-09-29
IL94983A (en) 1999-08-17
JPH07285853A (en) 1995-10-31
GB2265311B (en) 1994-02-09
LU87764A1 (en) 1992-03-11
SE512992C2 (en) 2000-06-12
JPH08198771A (en) 1996-08-06
HUT54037A (en) 1991-01-28
NO983923D0 (en) 1998-08-26
FI109334B (en) 2002-07-15
NO983923L (en) 1991-01-08
GR900100513A (en) 1991-12-10
AU687553B2 (en) 1998-02-26
AU2332195A (en) 1995-09-07
CY1965A (en) 1997-07-04
JP2001233897A (en) 2001-08-28
PT94628B (en) 1997-06-30
JPH07309897A (en) 1995-11-28
ATA144090A (en) 1999-08-15
IE64411B1 (en) 1995-08-09
DK162590A (en) 1991-01-08
FR2649319B1 (en) 1994-12-09
NL9001537A (en) 1991-02-01
GB9306204D0 (en) 1993-05-19
IT1241460B (en) 1994-01-17
BE1004486A3 (en) 1992-12-01
JPH0832624B2 (en) 1996-03-29
HK97695A (en) 1995-06-23
DK175849B1 (en) 2005-03-29
IE902435A1 (en) 1991-02-13
NO903001L (en) 1991-01-08
KR910002430A (en) 1991-02-25
AT406225B (en) 2000-03-27
JP2931773B2 (en) 1999-08-09
DE4021517A1 (en) 1991-01-17
FI20000059A (en) 2000-01-12
GB2234896B (en) 1994-01-19
NO903001D0 (en) 1990-07-05
FI20000060A (en) 2000-01-12
FI108611B (en) 2002-02-28
GB9014704D0 (en) 1990-08-22
IL94983A0 (en) 1991-06-10

Similar Documents

Publication Publication Date Title
IT9048113A0 (en) FORMULATIONS WITH PROTRACT RELEASE OF WATER SOLUBLE PEPTIDES (CASE 600-7110)
DE69027799T2 (en) Chemically amplified photoresist
KR900016481U (en) Buckle
DK111489D0 (en) PEPTIDES
KR900012343U (en) Holding connector for dome type tent
DK511188D0 (en) WATER SOLUBLE MONOESTERS
DK210590D0 (en) hirudin peptides
KR900016480U (en) buckle
DK197989A (en) peptide
DK380288D0 (en) HOW TO UNKNOWN PEPTIDES
KR900700503A (en) Peptide
KR950700901A (en) Antiviral peptides (ANTIVIRAL PEPTIDES)
NO177858C (en) Peptide
KR900700504A (en) Procalcitonin peptide
NO921698L (en) WATER SOLUBLE RESIN
KR900701833A (en) Angiogenic potentiationg peptide that assists angiogenic factors
FI101474B1 (en) Solid-phase peptide synthesis
SE8802429D0 (en) PEPTIDE ANALOGUES
DK258788D0 (en) PEPTID PREPARATION
KR900011924U (en) Tack connector
BR6900473U (en) STEM CONNECTOR
KR910010599U (en) buckle
ZA905327B (en) Sustained release formulations of water soluble peptides
CY1844A (en) Sustained release formulations of water soluble peptides
DK381789D0 (en) PEPTIDES

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970623